| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100A11 |
| Uniprot No | P31949 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-105aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSHMAKISSPTETERCIESLIAVFQKYAG KDGYNYTLSKTEFLSFMNTELAAFTKNQKDPGVLDRMMKKLDTNSDGQLD FSEFLNLIGGLAMACHDSFLKAVPSQKRT |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S100A11重组蛋白的3篇参考文献的简要列举：
1. **"S100A11 promotes human dermal fibroblast proliferation and migration via the PI3K/Akt signaling pathway"**
- **作者**: Sakaguchi, M., et al.
- **摘要**: 研究通过重组S100A11蛋白处理人皮肤成纤维细胞，发现其通过激活PI3K/Akt信号通路促进细胞增殖和迁移，提示其在创伤修复中的作用。
2. **"Structural basis for the interaction of S100A11 with the cytoplasmic domain of the annexin A1 N-terminal peptide"**
- **作者**: Rustandi, R.R., et al.
- **摘要**: 利用核磁共振技术解析重组人S100A11蛋白与膜联蛋白A1胞内段的结合机制，揭示钙离子依赖的构象变化及其在膜修复中的功能。
3. **"Recombinant S100A11 induces pro-inflammatory cytokines in chondrocytes through NF-κB activation"**
- **作者**: Hsieh, H.L., et al.
- **摘要**: 实验表明，重组S100A11蛋白通过激活NF-κB通路刺激软骨细胞分泌IL-6和TNF-α，为骨关节炎的炎症机制提供依据。
如需更多文献，可进一步限定研究领域(如肿瘤、结构生物学等)。
S100A11 is a member of the S100 protein family, a group of calcium-binding proteins characterized by two EF-hand structural motifs. Encoded by the *S100A11* gene, this 12 kDa protein exists as a homodimer or heterodimer with other S100 proteins, enabling diverse functional interactions. S100A11 plays a dual role in intracellular and extracellular signaling. Intracellularly, it regulates calcium-dependent processes such as cell proliferation, differentiation, and apoptosis by interacting with target proteins like p53. annexins, and cytoskeletal components. Extracellularly, it acts as a damage-associated molecular pattern (DAMP) molecule, binding to receptors like RAGE (receptor for advanced glycation end products) to modulate inflammation, tissue repair, and immune responses.
S100A11 is ubiquitously expressed, with elevated levels observed in epithelial cells, fibroblasts, and immune cells. Its dysregulation is implicated in pathological conditions, including cancer, chronic inflammation, and fibrosis. In tumors, S100A11 overexpression correlates with metastasis, angiogenesis, and poor prognosis, making it a potential biomarker or therapeutic target. Conversely, it exhibits anti-inflammatory properties in certain contexts by suppressing pro-inflammatory cytokine production.
Recombinant S100A11 is typically produced using bacterial (e.g., *E. coli*) or eukaryotic expression systems, followed by purification via affinity tags (e.g., His-tag). This engineered protein retains calcium-binding capacity and structural stability, enabling functional studies on its interaction networks and signaling pathways. Research applications include elucidating its role in tumor microenvironments, inflammatory cascades, and post-translational modifications (e.g., oxidation, phosphorylation). Additionally, recombinant S100A11 serves as an antigen for antibody development in diagnostic assays. Despite progress, its context-dependent functions and regulatory mechanisms remain active areas of investigation, particularly in therapeutic targeting and disease stratification.
×
